Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12892644 | 0.85 | QDPR (0.60) | QDPR | |
| SCHEMBL13591401 | 0.84 | QDPR (0.49) | QDPRWNT3A | |
| SCHEMBL12878759 | 0.83 | KDM4E (0.41) | WNT3A | |
| SCHEMBL13490629 | 0.79 | CCR1 (0.48) | QDPRWNT3A | |
| SCHEMBL8488039 | 0.79 | SIGMAR1 (0.53) | QDPR | |
| SCHEMBL18113625 | 0.79 | ALDH1A1 (0.49) | WNT3A | |
| SCHEMBL13161937 | 0.78 | QDPR (0.49) | QDPR | |
| SCHEMBL21266741 | 0.78 | QDPR (0.46) | QDPRWNT3A | |
| SCHEMBL13490635 | 0.77 | QDPR (0.45) | QDPRWNT3A | |
| SCHEMBL21038282 | 0.77 | SLC6A4 (0.46) | QDPRWNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | QDPR 546/4885WNT3A 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.